A study testing whether a new weekly shot from Regeneron Pharmaceuticals, olatorepatide, can help with weight.
What this means for you
- Who can join
- Adults 18 to 65, have obesity or are overweight, BMI 27+.
- What you take
- olatorepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The study runs about 9 months.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Overweight or Obesity.
Full scientific study title: Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US.
Who can join
Adults 18 to 65, have obesity or are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Body mass index >=27.0 kg/m^2 to <45.0 kg/m^2 at screening
- Demonstrates ability and willingness to comply with the study protocol, including attending all scheduled visits, adhering to the prescribed treatment regimen, and completing all required assessment
Key exclusion criteria
- History of Type 1 or Type 2 diabetes
- Change in body weight >5 kg within approximately 3 months before screening as described in the protocol
- Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions, prior to randomization or planned during the study period
- History of any of the following conditions: acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones or has a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years as described in the protocol
Where this study is enrolling
This trial has 3 sites across 3 states. Contact a site coordinator directly to start screening.
California1 site
- Diablo Clinical Research - Flourish ResearchWalnut Creek, California
Florida1 site
- Clinical Site Partners, LLC DBA Flourish ResearchWinter Park, Florida
Texas1 site
- Flourish Research - San Antonio Medical TrialsSan Antonio, Texas
Timeline
Started enrolling: 2026-03-16. Expected completion: 2026-12-28. Last updated on ClinicalTrials.gov: 2026-04-29.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
